LifeStance Health Group (LFST)
(Delayed Data from NSDQ)
$5.28 USD
-0.07 (-1.31%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $5.28 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LFST 5.28 -0.07(-1.31%)
Will LFST be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for LFST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFST
LifeStance Health Group (LFST) Reports Q1 Loss, Tops Revenue Estimates
RadNet (RDNT) Q1 Earnings and Revenues Surpass Estimates
LFST: What are Zacks experts saying now?
Zacks Private Portfolio Services
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
LifeStance Health (LFST) Soars 6.6%: Is Further Upside Left in the Stock?
Will LifeStance Health Group (LFST) Report Negative Earnings Next Week? What You Should Know
Other News for LFST
Mikra Completes Design of New Product and Advances Shipment Date
Lifeist Wellness’s Mikra Unveils FOCUS Ahead of Schedule
Buy Rating on LifeStance Health Group: Strong Growth and Margin Expansion Potential with Significant Upside
Global Weed Business: Flora Buys Australian Vaporizers As IM Cannabis Doubles Down On Germany
Lifeist Wellness Refocuses with Strategic Divestiture